Press Release

May 8, 2024
Eli Lilly Japan K.K.
Mitsubishi Tanabe Pharma Corporation

Announcement of Approval Submission andMarketing Alliance in Japanfor Tirzepatide as a Drug for Obesity Disease
Eli Lilly Japan K.K. (head office: Kobe, Hyogo; Representative Director and President: Simone
Thomsen; hereinafter referred to as "Eli Lilly Japan") and Mitsubishi Tanabe Pharma Corporation (headoffice: Osaka, Osaka; Representative Director: Akihiro Tsujimura; hereinafter referred to as "MTPC")
announced that Eli Lilly Japan had applied for approval of tirzepatide (hereinafter referred to as "theproduct") from the Ministry of Health, Labour and Welfare and the two companies will form a marketingalliance in Japan.
Based on the marketing alliance between the two companies, Eli Lilly Japan will obtain the manufacturingand marketing approval for the product, and Mitsubishi Tanabe Pharma will distribute and market theproduct after obtaining the approval, similar to the long-acting GIP/GLP-1 receptor agonist "Mounjaro®
Subcutaneous Injection" (generic name: tirzepatide, hereinafter referred to as "Mounjaro"), which is thesame compound and for which both companies tied up for sales in 2023. Activities to provide information
to healthcare professionals will be conducted jointly by the two companies.
Eli Lilly Japan and Mitsubishi Tanabe Pharma will work more closely than ever before through themarketing alliance of Mounjaro and this product to contribute to the further advancement of medicalcare for more fulfilling lives of people living with type 2 diabetes and obesity disease in Japan.

<REFERENCE INFORMATION>
About Tirzepatide
Tirzepatide is the world's first long-acting GIP/GLP-1 receptor agonist that acts as a single molecule on
two receptors, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
Although the structure of this product is a single molecule based on the natural GIP peptide sequence, it
has been modified to also bind to the GLP-1 receptor and acts selectively for a long time. Mounjaro®
Subcutaneous Injection, a new product for type 2 diabetes, was launched in Japan in April 2023, and six
doses ranging from 2.5 mg to 15 mg are available. It was approved in the U.S. for the treatment of obesity
disease in November 2023 and is marketed under the brand name ZepboundTM.

1/2

Obesity disease
In Japan, obesity is defined as excessive accumulation of fat in adipose tissue, with body mass index(BMI) of 25 or higher. On the other hand, obesity disease is defined as a condition in which one isobese and has or is expected to have complicated health problems caused by or related to obesity,requiring medical weight loss. Obesity and obesity disease are caused by not only lifestyle but also
various factors such as heredity and environment, and said to be closely related to various other healthdisorders.
About Eli Lilly Japan
Eli Lilly Japan K.K. is a subsidiary of US-based Eli Lilly and Company. It contributes to medical
treatment in Japan through the development, manufacture, import and sale of innovative
pharmaceutical products that enable people to live longer, healthier, and more fulfilling lives, focusing
on the therapeutic areas such as cancer, diabetes, musculoskeletal diseases, central nervous systemdiseases, autoimmune diseases, growth disorder, and pain. For more information, visit
http://www.lilly.co.jp
About Mitsubishi Tanabe Pharma CorporationMitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG),
is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethicalpharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s
pharmaceutical industry. MCG has positioned health care as its strategic focus in its management
policy, “Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that
end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetesand kidney, and cancer. MTPC is focusing on “precision medicine” to provide drugs with high treatment
satisfaction by identifying patient populations with high potential for efficacy and safety. In addition,
MTPC is working to develop “around the pill solutions” to address specific patient concerns based ontherapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of
aggravation and prognosis. For more information, go to https://www.mt-pharma.co.jp/e/2/2